Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes
Reps are promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.
Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.
Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.